Proton beam therapy and the convoluted pathway to incorporating emerging technology into routine medical care in the United States

Cancer Journal

Volumn 15, Issue 4, 2009, Pages 333-338

  Steinberg, Michael L ^a   Konski, Andre ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomedical; Emerging medical technology; Evidence based medicine; Proton beam therapy; Technology assessment

Indexed keywords

BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEAD AND NECK CANCER; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; MEDICAL CARE; MEDULLOBLASTOMA; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; REVIEW; SARCOMA; UNITED STATES;

COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HEALTH POLICY; HUMANS; INSURANCE COVERAGE; NEOPLASMS; PROTONS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TECHNOLOGY, RADIOLOGIC; UNITED STATES;

EID: 69549113181     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181af5b5c     Document Type: Review

References (30)

1. Davis K. Slowing the growth of health care costs - learning from international experience. N Engl J Med. 2008;359:1751-1755.
2. Neumann PJ, Kamae MS, Palmer JA. Medicare's national coverage decisions for technology, 1999-2007. Health Aff. 2008;27:1620-1631.
3. Deyo RA, Patrick DL. Hope of Hype. New York: AMACOM Press; 2005.
4. Steinberg ML. Health policy and healthcare economics observed. Semin Radiat Oncol. 2008;18:149-151.
5. Steinbrook R. Saying No isn't NICE - travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med. 2008;359:1977-1981.
6. Tunis S. Medicare Coverage of New Technology. PowerPoint presentation. September 3, 2003.
7. Tunis S. Testimony to Medicare Evidence Development & Coverage Advisory Committee. April 30, 2008.
8. Staube B. Testimony to Medicare Evidence Development & Coverage Advisory Committee. April 30, 2008.
9. American Medical Association. CPT Process - How a Code Becomes a Code. Available at: http://www.ama-assn.org/ama/no-index/physician-resources/3882. shtml. Accessed March 31, 2009.
10. Glimelius B, Ask A, Bjelkengren G, et al. Number of patients potentially eligible for proton therapy. Acta Oncol. 2005;44:836-849. (Pubitemid 41780109)
11. Loma Linda University Medical Center. Welcome to Proton Therapy! Available: http://www.protons.com/proton-therapy. Accessed March 31, 2009.
12. Nguyen PL, Trofimov A, Zietman AL. Proton-beam vs. intensity-modulated radiation therapy: which is best for treating prostate cancer? Oncology (Williston Park). 2008;22:748-754. (Pubitemid 352007336)
13. Olsen DR, Bruland OS, Fryholm G, et al. Proton therapy - a systematic review of clinical effectiveness. Radiother Oncol. 2007;83:123-132. (Pubitemid 46776914)
14. Institute for Clinical and Economic Review. Brachytherapy & Proton Beam Therapy for Treatment of Clinically-Localized, Low-Risk Prostate Cancer. Final appraisal document. December 22, 2008.
15. Brada M, Pijls-Johannesma M. Proton therapy in clinical practice. J Clin Oncol. 2007;25:965-970.
16. Pljls-Johannesma M, Cost-effectiveness of particle therapy: current evidence and future needs. Radiother Oncol. 2008;89:127-134.
17. Freedman, B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
18. Goitein M, Cox JD. Should randomized clinical trials be required in proton therapy? J Clin Oncol. 2008;26:175-176.
19. Tepper J. Protons and Parachutes. J Clin Oncol. 2008;26:2436-2437.
20. Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trials be required before proton therapy is more widely adopted? Radiother Oncol. 2008;86:148-153.
21. Lundkvist J, Ekman M, Ericsson, SR, et al. Proton therapy of cancer: Potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44:850-861. (Pubitemid 41780110)
22. Lundkvist J, Ekman M, Ericsson SR, et al. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol. 2005;75:179-185. (Pubitemid 40805247)
23. Konski A, Speier W, Hanlon A, et al. Is proton therapy cost-effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007;25:3603-3608. (Pubitemid 47372597)
24. Medicare's coverage with evidence development: a policy-making tool in evolution. J Oncol Prac. 2007;3:296-301.
25. Comparative effectiveness: Its origin, evolution, and influence on health care. J Oncol Prac. 2009;2:80-82.
26. Stevens CW, Glatstein E. Beware the medial-industrial complex. Oncologist. 1996;1:IV-V.
27. Bentzen SM. Randomized controlled trials in health technology assessment: overkill or overdue? Radiother Oncol. 2008;86:142-147.
28. Dahl O. Protons: a step forward or perhaps only more expensive radiation therapy? Acta Oncol. 2005;44:798-800. (Pubitemid 41780104)
29. Halperin EC. Randomized prospective trials of innovative radiotherapy technology are necessary. J Am Coll Radiol. 2009;6:33-37.
30. Emanuel EJ, Fuchs VR, Garber AM. Essential elements of a technology and outcomes assessment initiative. JAMA. 2007;298:1323-1325.